Thomas Galbo

Thomas Galbo is a seasoned biomedical professional with extensive experience in advisory and leadership roles across various companies. Currently serving as an Advisor at both Moonlight Bio and Leveragen while also advising Kelonia Therapeutics, Galbo previously held positions such as Chief Business and Operating Officer at Hillstar Bio and Chief Business Officer at Kelonia Therapeutics. Notably, experience includes a significant tenure at bluebird bio, where roles included Vice President of Oncology Corporate Development and Program Leader for the ABECMA CAR T Program. Additional experience encompasses consulting at The Boston Consulting Group and research at Yale University School of Medicine. Galbo holds a PhD in endocrinology from the University of Copenhagen, where previous studies also culminated in MSc and BSc degrees in Molecular Biomedicine.